Investor Relations

Company Overview

Conversion Labs, Inc. (the "Company") is a health and wellness focused e-commerce company with a portfolio of online direct-to-consumer brands. Our portfolio of brands includes proprietary over-the-counter products as well as over 1000 prescription medications we are licensed to sell in all 50 states and the District of Columbia through our joint venture partner,  We also provide online physician consultations directly to consumers in all 50 states.  In addition to our healthcare platform, Conversion Labs owns 51% of PDFSimpli, an online direct-response software as a service business that allows users to convert, edit, sign and share PDF files. 


Publicly traded on OTCQB

$14 Million

revenue run-rate and growing

850 million

ad impressions served in 2 years

50 states

licensed for online Rx & consults


Deloitte's 2018 Teschnology Fast 500

Stock Information






52 week Low/High

Day Low/High

Latest 10-K

View Latest 10-K


Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is the source of our success.

Investor Contact Information


Conversion Labs, Inc.
800 Third Avenue
Suite 2800
New York, NY 10022

Investor Relations

T: 866-351-5907 Ext: 5

Transfer Agent

Worldwide Stock Transfer, LLC
One University Plaza, Suite 505
Hackensack, NJ 07601